The utilization of Peritoneal Dialysis (PD) has been increasing in the past decade owing to various government initiatives and recognition of benefits like better preservation of residual renal function, quality of life, and lower cost. The Advancing American Kidney Health initiative aims to increase the utilization of home therapies like PD and kidney transplantation to treat end-stage kidney disease (ESKD). A natural consequence of this development is that more patients will do PD, and many will eventually undergo kidney transplantation. Therefore, it is important to understand the effect of pre-transplant PD on post-transplant outcomes like delayed graft function (DGF), rejection, thrombosis, graft, and patient survival. Furthermore, some of these patients may develop DGF, which raises the question of the utility of PD during DGF and its risks. While transplant is the best renal replacement therapy option, it is not everlasting, and many transplant recipients must go on dialysis after allograft failure. Can PD be a good option for these patients? This is another critical question. Furthermore, a significant proportion of non-renal solid organ transplant recipients develop ESKD. Is PD feasible in this group? In this review, we try to address all of these questions in the light of available evidence.